esmolol ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
beta-adrenoreceptor antagonists 1054 81147-92-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • esmolol
  • brevibloc
  • esmolol hydrochloride
  • esmolol HCl
a beta1-selective (cardioselective) adrenergic receptor blocking agent with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity at therapeutic dosages
  • Molecular weight: 295.38
  • Formula: C16H25NO4
  • CLOGP: 1.72
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 67.79
  • ALOGS: -3.31
  • ROTB: 10
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2.50 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 20 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.68 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 1.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 290 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.59 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.15 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,IKBKB,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK7,NTRK2,PDK2,PDK4,PIK3CB,PIM2,PLK1,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,ZAP70 39
kinase-selectivity-class CDK4,EIF2AK3,PDK4 3
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 1.023 Moderate 0.70
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 Moderate 0.70
rat-kpuu-brain Rat brain Kpuu 0.501 % Moderate 0.70

Approvals:

DateAgencyCompanyOrphan
Dec. 31, 1986 FDA BAXTER HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 165.11 71.36 125 828 1384173 89243321

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 175.99 43.15 141 1056 630056 41990082
Bradycardia 64.36 43.15 36 1161 85448 42534690
Cardiac arrest 58.66 43.15 37 1160 109283 42510855
Hypotension 58.65 43.15 52 1145 257579 42362559
Pulseless electrical activity 43.42 43.15 14 1183 8423 42611715

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 288.95 40.37 231 1864 1520309 109066895
Cardiac arrest 100.13 40.37 56 2039 196697 110390507
Bradycardia 67.61 40.37 40 2055 155477 110431727
Hypotension 53.10 40.37 57 2038 523792 110063412
Anaesthetic complication neurological 52.41 40.37 10 2085 1023 110586181
Neuromuscular block prolonged 50.53 40.37 10 2085 1237 110585967
Pulseless electrical activity 47.10 40.37 16 2079 16741 110570463
Apallic syndrome 45.61 40.37 9 2086 1097 110586107

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C07AB09 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS
Beta blocking agents, selective
FDA MoA N0000000161 Adrenergic beta-Antagonists
FDA EPC N0000175556 beta-Adrenergic Blocker
MeSH PA D000319 Adrenergic beta-Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018663 Adrenergic Agents
MeSH PA D018674 Adrenergic Antagonists
MeSH PA D058671 Adrenergic beta-1 Receptor Antagonists
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35530 ฮฒ-adrenergic antagonist
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:38070 anti-arrhythmia drug
CHEBI has role CHEBI:176497 geroprotector
CHEBI has role CHEBI:35674 antihypertensive agent

Related Drugs by ATC class:

C07AB Beta blocking agents, selective 13 drugs
acebutololatenololbetaxololbevantololbisoprololceliprololepanololesatenolollandiololmetoprololnebivololpractolol show all 13 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Supraventricular tachycardia indication 6456007
Atrial fibrillation indication 49436004 DOID:0060224
Perioperative hypertension indication 434711000124103
Perioperative Tachycardia indication
Malignant essential hypertension off-label use 78975002 DOID:10823
Dissection of aorta off-label use 308546005
Acute coronary syndrome off-label use 394659003
Hypertensive urgency off-label use 443482000
Prevention of Hypertension in Pheochromocytoma off-label use
Bronchospasm contraindication 4386001
Anaphylaxis contraindication 39579001
Sinus bradycardia contraindication 49710005
Diabetes mellitus contraindication 73211009 DOID:9351
Pulmonary emphysema contraindication 87433001
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Decompensated cardiac failure contraindication 195111005
Heart block contraindication 233916004
Acute exacerbation of asthma contraindication 708038006




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.19 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Beta-1 adrenergic receptor GPCR ANTAGONIST Ki 6.90 IUPHAR IUPHAR
Beta-2 adrenergic receptor GPCR Kd 5.20 CHEMBL
Beta-1 adrenergic receptor GPCR Kd 7 CHEMBL

External reference:

IDSource
4019746 VUID
N0000147837 NUI
D00644 KEGG_DRUG
81161-17-3 SECONDARY_CAS_RN
4019349 VANDF
4019746 VANDF
C0116569 UMLSCUI
CHEBI:4856 CHEBI
CHEMBL768 ChEMBL_ID
CHEMBL1201115 ChEMBL_ID
DB00187 DRUGBANK_ID
C036604 MESH_SUPPLEMENTAL_RECORD_UI
59768 PUBCHEM_CID
7178 IUPHAR_LIGAND_ID
5365 INN_ID
MDY902UXSR UNII
151448 RXNORM
3762 MMSL
4681 MMSL
47065 MMSL
d00224 MMSL
001861 NDDF
004745 NDDF
35318005 SNOMEDCT_US
372847006 SNOMEDCT_US
77856005 SNOMEDCT_US
MDY902UXSR INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Esmolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0404-9785 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 17 sections
Brevibloc HUMAN PRESCRIPTION DRUG LABEL 1 0404-9825 INJECTION 10 mg INTRAVENOUS NDA 25 sections
Brevibloc HUMAN PRESCRIPTION DRUG LABEL 1 0404-9825 INJECTION 10 mg INTRAVENOUS NDA 25 sections
ESMOLOL HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0404-9858 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 17 sections
Esmolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0641-2965 INJECTION 10 mg INTRAVENOUS NDA 17 sections
Brevibloc HUMAN PRESCRIPTION DRUG LABEL 1 10019-055 INJECTION 10 mg INTRAVENOUS NDA 25 sections
Brevibloc HUMAN PRESCRIPTION DRUG LABEL 1 10019-055 INJECTION 10 mg INTRAVENOUS NDA 25 sections
Brevibloc HUMAN PRESCRIPTION DRUG LABEL 1 10019-075 INJECTION 20 mg INTRAVENOUS NDA 25 sections
Brevibloc HUMAN PRESCRIPTION DRUG LABEL 1 10019-075 INJECTION 20 mg INTRAVENOUS NDA 25 sections
Brevibloc HUMAN PRESCRIPTION DRUG LABEL 1 10019-115 INJECTION 10 mg INTRAVENOUS NDA 25 sections
Brevibloc HUMAN PRESCRIPTION DRUG LABEL 1 10019-115 INJECTION 10 mg INTRAVENOUS NDA 25 sections
Esmolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10019-120 INJECTION 10 mg INTRAVENOUS NDA 26 sections
BREVIBLOC HUMAN PRESCRIPTION DRUG LABEL 1 10019-666 INJECTION 20 mg INTRAVENOUS NDA 26 sections
BREVIBLOC HUMAN PRESCRIPTION DRUG LABEL 1 10019-666 INJECTION 20 mg INTRAVENOUS NDA 26 sections
BREVIBLOC HUMAN PRESCRIPTION DRUG LABEL 1 10019-668 INJECTION 20 mg INTRAVENOUS NDA 26 sections
BREVIBLOC HUMAN PRESCRIPTION DRUG LABEL 1 10019-670 INJECTION 10 mg INTRAVENOUS NDA 26 sections
BREVIBLOC HUMAN PRESCRIPTION DRUG LABEL 1 10019-670 INJECTION 10 mg INTRAVENOUS NDA 26 sections
BREVIBLOC HUMAN PRESCRIPTION DRUG LABEL 1 10019-672 INJECTION 10 mg INTRAVENOUS NDA 26 sections
esmolol hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 25021-308 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 27 sections
esmolol hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 25021-309 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 27 sections
Esmolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 44567-450 INJECTION 10 mg INTRAVENOUS ANDA 28 sections
Esmolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 44567-451 INJECTION 20 mg INTRAVENOUS ANDA 28 sections
Esmolol Hydrochloride in Water HUMAN PRESCRIPTION DRUG LABEL 1 44567-811 INJECTION 10 mg INTRAVENOUS NDA 20 sections
Esmolol Hydrochloride in Water HUMAN PRESCRIPTION DRUG LABEL 1 44567-812 INJECTION 20 mg INTRAVENOUS NDA 20 sections
Esmolol Hydrochloride Human Prescription Drug Label 1 50090-4512 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 25 sections
Esmolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-4699 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 25 sections
ESMOLOL HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1322 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 18 sections
ESMOLOL HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1371 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 18 sections
ESMOLOL HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1427 INJECTION 10 mg INTRAVENOUS NDA 18 sections
ESMOLOL HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1444 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 18 sections